The improvements in stent flexibility and biocompatibility have lead to the conclusion by Dr. Mitchell Krucoff that second-generation drug eluting-stents, such as Abbott's Xience stent, result in an improved ability to prevent restenosis following angioplasty and stent implantation. See an excerpt from India's pharmabiz.com (which also highlights the market potential for coronary stents in India): [...]
During the course of my review of recent premarket approvals (PMAs), I was once again startled (although I certainly shouldn’t be, having not too long ago done this same exercise on patent approvals) by the dominance of Medtronic. As an exercise (because exercise is important), I decided to just graph the January 2009 premarket approvals [...]
I offer a set of perspectives from ITECS Insider on the most significant headlines in the medical device industry in 2008 with potential impact in 2009. I recommend you read them in full, but here are the highlights of opinion: "Nothing will impact the medical device manufacturing industry in 2009 more than the subprime mortgage meltdown [...]
Typical exit strategies for medical technology companies who have succeeded in developing and commercializing their products include IPO, but the prospects for this strategy have diminished in recent years. With global financial markets in disarray as they wait breathlessly to see where and when the bottom will be, the prospects for entrance, let alone exit, [...]
In last week’s Wall Street Journal, Stephen Oesterle, the vice president for medicine and technology at Medtronic was paraphrased for his startling conclusion that medical devices are “finished”. His point, “You can’t keep stuffing gizmos into people to treat end-stage disease… When biotechnology gets right, we’re finished. Because it’s restorative, not palliative as devices are.” [...]
Contact:
